Latest Board Changes News

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

TechnologyOne has upgraded its FY26 profit and recurring revenue growth forecasts, citing strong confidence in AI-enhanced SaaS+ products and a robust customer pipeline across key markets.

Celsius Resources has appointed Peter Hume as interim chairman while progressing the sale of its Opuwo project and reclaiming a key 60% shareholding in its Philippine affiliate after funding obligations were unmet.

Cauldron Energy has announced a major uranium resource upgrade at its Yanrey Project in Western Australia, now exceeding 55 million pounds of uranium oxide. Backed by strong project economics and fully funded drilling for 2026, the company is poised to capitalise on the global nuclear resurgence amid ongoing policy challenges.

SRG Global Limited posted a robust half-year result for December 2025, driven by strong segment growth and the acquisition of Total AMS Pty Ltd. The company also raised its interim dividend, signalling confidence in its outlook.

H&G High Conviction Limited has significantly reduced its half-year loss following asset divestment and is actively exploring strategic alternatives to enhance shareholder value amid looming ASX re-compliance requirements.

Pengana International Equities reported a half-year net profit of $4.6 million, down from $26.9 million last year, while announcing an increased fully franked dividend and initiating a strategic review to address shareholder concerns.

Emu NL has reversed its previous decision to terminate Doug Grewar, reinstating him as CEO and Managing Director with a new contract focused on advancing the Yataga Copper Project.

Dusk Group Limited has reported a solid 5.2% increase in net profit for the half year ended December 2025, alongside a 5.1% rise in revenue. The company also announced a fully franked interim dividend doubling the prior payout, signalling confidence in its retail operations.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

humm Group Limited has posted a statutory profit after tax of $13.9 million for the half-year ended 31 December 2025, marking a 49% decline from the previous year, driven by increased credit losses and legal costs. Despite challenges, the company declared a fully franked interim dividend of 1.5 cents per share.